These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 28219440)

  • 1. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.
    Wang YT; Edison P
    Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.
    Murugan NA; Nordberg A; Ågren H
    ACS Chem Neurosci; 2021 Jul; 12(13):2437-2447. PubMed ID: 34152739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual tracer tau PET imaging reveals different molecular targets for
    Chiotis K; Stenkrona P; Almkvist O; Stepanov V; Ferreira D; Arakawa R; Takano A; Westman E; Varrone A; Okamura N; Shimada H; Higuchi M; Halldin C; Nordberg A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1605-1617. PubMed ID: 29752516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau PET imaging in neurodegenerative tauopathies-still a challenge.
    Leuzy A; Chiotis K; Lemoine L; Gillberg PG; Almkvist O; Rodriguez-Vieitez E; Nordberg A
    Mol Psychiatry; 2019 Aug; 24(8):1112-1134. PubMed ID: 30635637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
    Ono M; Sahara N; Kumata K; Ji B; Ni R; Koga S; Dickson DW; Trojanowski JQ; Lee VM; Yoshida M; Hozumi I; Yoshiyama Y; van Swieten JC; Nordberg A; Suhara T; Zhang MR; Higuchi M
    Brain; 2017 Mar; 140(3):764-780. PubMed ID: 28087578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in Tau PET Imaging.
    Zimmer ER; Leuzy A; Gauthier S; Rosa-Neto P
    Can J Neurol Sci; 2014 Sep; 41(5):547-53. PubMed ID: 25424608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau PET Imaging.
    Higuchi M
    Adv Exp Med Biol; 2019; 1184():217-230. PubMed ID: 32096041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau PET imaging in Alzheimer's disease.
    Okamura N; Harada R; Furumoto S; Arai H; Yanai K; Kudo Y
    Curr Neurol Neurosci Rep; 2014 Nov; 14(11):500. PubMed ID: 25239654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Lagarde J; Olivieri P; Caillé F; Gervais P; Baron JC; Bottlaender M; Sarazin M
    J Neurol; 2019 Dec; 266(12):3087-3097. PubMed ID: 31535269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head to head comparison of [
    Jang YK; Lyoo CH; Park S; Oh SJ; Cho H; Oh M; Ryu YH; Choi JY; Rabinovici GD; Kim HJ; Moon SH; Jang H; Lee JS; Jagust WJ; Na DL; Kim JS; Seo SW
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):432-442. PubMed ID: 29143870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Tau and Its Ligands in PET Imaging.
    Harada R; Okamura N; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Biomolecules; 2016 Jan; 6(1):7. PubMed ID: 26751494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the development of tau PET radiotracers and their clinical applications.
    Okamura N; Harada R; Furukawa K; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Ageing Res Rev; 2016 Sep; 30():107-13. PubMed ID: 26802556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective.
    Ricci M; Cimini A; Camedda R; Chiaravalloti A; Schillaci O
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models.
    Ni R; Ji B; Ono M; Sahara N; Zhang MR; Aoki I; Nordberg A; Suhara T; Higuchi M
    J Nucl Med; 2018 Jun; 59(6):960-966. PubMed ID: 29419480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging biomarkers in tauopathies.
    Dani M; Edison P; Brooks DJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S26-8. PubMed ID: 26299160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau imaging with PET: an overview of challenges, current progress, and future applications.
    Robertson JS; Rowe CC; Villemagne VL
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):405-413. PubMed ID: 28750496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
    Murugan NA; Chiotis K; Rodriguez-Vieitez E; Lemoine L; Ågren H; Nordberg A
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1369-1382. PubMed ID: 30919054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tau Positron Emission Tomography: Applications in Diagnosis and Prognosis of Various Diseases].
    Takahata K; Kubota M; Kurose S; Higuchi M
    Brain Nerve; 2024 Sep; 76(9):1035-1044. PubMed ID: 39251223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.